## Drug Summary
Flunisolide, also known under brand names such as AeroBid, Nasalide, and Nasarel, is a synthetic corticosteroid primarily used in the maintenance treatment of asthma as a prophylactic therapy. It is available in different formulations, including as an oral metered-dose inhaler for asthma and as a nasal spray for allergic rhinitis. The drug is known to suppress inflammation and immune responses by acting as a glucocorticoid receptor agonist. Its pharmacokinetics include rapid absorption and primarily hepatic metabolism where it is converted into the S beta-OH metabolite. The efficacy of flunisolide is evident in its ability to alleviate symptoms common to allergic rhinitis such as rhinorrhea, nasal congestion, and sneezing by controlling the biosynthesis of inflammatory mediators like prostaglandins and leukotrienes.

## Drug Targets, Enzymes, Transporters, and Carriers
Flunisolide functions primarily by activating the glucocorticoid receptor, specifically binding to the NR3C1 gene product, thereby exerting anti-inflammatory effects. The drug is metabolized predominantly by the enzyme cytochrome P450 3A4 (CYP3A4), which is crucial for its biotransformation into active metabolites. It does not actively engage any specific transporters as per the provided data. The drug binds to the corticosteroid-binding globulin (coded by the gene SERPINA6), which regulates its bioavailability and activity; this protein-carrier interaction is significant in modulating the systemic effects of flunisolide.

## Pharmacogenetics
The pharmacogenetic profile of flunisolide involves significant interactions with the CYP3A4 enzyme. Genetic variants in the CYP3A4 gene can influence the metabolism of flunisolide, affecting both the drug's efficacy and patient's response to treatment. For instance, polymorphisms that lead to enhanced enzyme activity might result in reduced drug levels and efficacy, whereas lowered enzyme activity due to certain genetic variants could increase drug levels, potentially elevating the risk of side effects. However, the specific pharmacogenetic data for flunisolide has not been thoroughly outlined in the provided information, and further research could provide deeper insights into its pharmacogenetic implications, particularly considering its interaction with the glucocorticoid receptor and corticosteroid-binding globulin.